This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Colorectal Surgery  • Surgical Oncology  • Diagnosis  • Gastrointestinal Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Arch Surg. 2008;143(7):712.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Answer: Inflammatory Myofibroblastic Tumor

Primary small-bowel tumors are rare, with 5300 cases per year.¹ In order, the main tumors are adenocarcinoma, carcinoid, lymphoma, and gastrointestinal stromal tumor.¹ Inflammatory myofibroblastic tumors (IMTs), also known as pseudosarcomatous myofibroblastic proliferation, inflammatory sarcoma, Vanek tumor, plasma cell granuloma, and inflammatory myohistiocytic proliferation, are even rarer.²

An IMT is a rare, benign, neoplastic mass that consists of an inflammatory infiltrate with plasma cells, eosinophils, and lymphocytes. Granulation tissue can also be seen. There is recent evidence that IMTs are more neoplastic than reactive, associated with p22-24 of chromosome 2 with anaplastic lymphoma kinase expression.² This lends favor to IMTs being a neoplasm from the mesoderm due to chromosome defects, in the same group as Ewing sarcoma and alveolar rhabdomyosarcoma.²

These lesions or masses can occur anywhere in the body of young adults and small children and are usually limited to soft tissue and submucosal tissue.² The most commonly reported . . . [Full Text of this Article]

AUTHOR INFORMATION



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Image of the Month—Quiz Case
Raman Kumar and Elizabeth A. Bender
Arch Surg. 2008;143(7):711.
EXTRACT | FULL TEXT